BECN1 and neoplasm: The H3K18la modification enhances transcription of rubicon-like autophagy enhancer (RUBCNL/Pacer), mediating the recruitment of the PtdIns3K complex through interaction with Beclin 1 (BECN1), thereby promoting the maturation of autophagosomes and enhancing tumor cell resistance to bevacizumab (83).